Drugs / DB-3Q
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07625293 | Jun 2026 → Jun 2027 expected | Crohn disease | Direct Biologics, LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06918808 | May 2025 → Jul 2027 expected | perianal Crohn disease | Direct Biologics, LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-3Q | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06918808 ↗ |
| Modality | Other / unclassified | “acellular secretome proteins and extracellular vesicles” NCT06918808 ↗ |
| Route | Other | “direct injection” NCT06918808 ↗ |